Internal Medicine, Medical Oncology · Chicago, IL
NPI
1083649792
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
680 N Lake Shore Dr, Suite 1000
Chicago, IL, 60611
Phone (312) 695-9797
Medicare paid, 2024
$1.2M
55,077 services
Medicare patients, 2024
257
Average age 74
Drug cost, 2024
$4.1M
519 prescriptions
Company payments, 2025
$30K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jyoti Patel was code J9271 (injection, pembrolizumab, 1 mg), 6,200 times for 16 patients. In total Jyoti Patel billed 55,077 services in 89 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 6,200 | 16 | $44.80 | $278K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 5,040 | 15 | $2.34 | $12K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 4,350 | 24 | $0.12 | $505 |
| J9305 Injection, pemetrexed, not otherwise specified, 10 mg | Office | 2,320 | 20 | $3.64 | $8,447 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 424 | 37 | $0.09 | $38.14 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 360 | 29 | $0.70 | $253 |
| 99215 Office E&M - Established | Office | 240 | 95 | $135.75 | $33K |
| J9045 Injection, carboplatin, 50 mg | Office | 187 | 21 | $2.82 | $528 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 163 | 87 | $13.46 | $2,195 |
| 96375 Injection Administration | Office | 137 | 48 | $12.44 | $1,705 |
| 96413 Chemotherapy Administration | Office | 116 | 68 | $104.21 | $12K |
| 99214 Office E&M - Established | Office | 91 | 46 | $104.36 | $9,497 |
| 99443 Telephone Services | Office | 80 | 54 | $101.76 | $8,141 |
| 96372 Injection Administration | Office | 80 | 39 | $11.33 | $906 |
| 96367 Intravenous Infusion, Hydration | Office | 48 | 27 | $21.37 | $1,026 |
By year: 2022 $823K for 35,307 services; 2023 $550K for 25,275 services; 2024 $1.2M for 55,077 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 17 | 17 | $8.65 | $147 |
Medicare prescription drug claims, 2024
In 2024, the drug Jyoti Patel prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 127 prescriptions and refills. In total Jyoti Patel wrote 519 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 127 | 137 | 18 | $2.3M |
| Dexamethasone Generic | 56 | 60 | 30 | $1,315 |
| Alunbrig Brigatinib | 26 | 26 | Under 11 | $491K |
| Eliquis Apixaban | 26 | 30 | Under 11 | $17K |
| Prochlorperazine Maleate Generic | 25 | 25 | 18 | $200 |
| Levothyroxine Sodium Generic | 20 | 36 | Under 11 | $168 |
| Lorbrena Lorlatinib | 17 | 17 | Under 11 | $309K |
| Xarelto Rivaroxaban | 17 | 21 | Under 11 | $12K |
| Ondansetron Hcl Generic | 16 | 16 | 13 | $149 |
| Omeprazole Generic | 15 | 23 | Under 11 | $41.93 |
| Alecensa Alectinib Hcl | 15 | 19 | Under 11 | $275K |
| Ondansetron Odt Ondansetron | 14 | 14 | Under 11 | $180 |
| Tepmetko Tepotinib Hcl | 14 | 14 | Under 11 | $299K |
| Esomeprazole Magnesium Generic | 12 | 12 | Under 11 | $397 |
| Gabapentin Generic | 11 | 13 | Under 11 | $95.83 |
Brand drugs: 278 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jyoti Patel $30K ($23K in general payments such as food, travel and fees and $7,200 for research) from 8 companies. The largest payer was Abbvie Inc. with $15K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.